Biosensing
U.S. National Science Foundation
This opportunity closed. 5 similar opportunities are open right now.
Similar opportunities open now
- Biomedical Technology Optimization and Dissemination Center (BTOD) (RM1 - Clinical Trial Not Allowed)OpenNational Institutes of HealthCloses Jan 2029
- Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)OpenNational Institutes of HealthCloses Mar 2027
- Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)OpenNational Institutes of HealthCloses Mar 2027
- Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)OpenNational Institutes of HealthCloses Mar 2029Up to $250K
- NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)OpenNational Institutes of HealthCloses Jul 2029Up to $500K
About this archived opportunity
The Biosensing program is part of the Engineering Biology and Health cluster, which also includes 1) the Biophotonics program; 2) the Cellular and Biochemical Engineering program; 3) the Disability and Rehabilitation Engineering program; and 4) the Engineering of Biomedical Systems program. The Biosensing program supports fundamental engineering research in the monitoring, identification and/or quantification of biological analytes and phenomena using innovations that exist at the intersection of engineering, life sciences, and information technology. Projects submitted to the program must advance both engineering and life sciences. The Biosensing program encourages proposals that, in addition to advancing biosensing technology, address critical sensor needs in biomedical research, public health, food safety, agriculture, forensics, environmental protection, and homeland security. Proposals are especially encouraged in areas of critical need: sensing technologies that can enable monitoring and surveillance of the environment and/or individuals for novel infectious agents; platform technologies that can readily be modified as soon as new agents are detected, sequenced, and/or otherwise characterized to enable rapid deployment of sensors in clinics and the environment; and adaptive and/or multiplex sensing technologies that can help the nation prevent the spread of the next global pandemic. Major areas of interest for the program include: Novel signal transduction principles and mechanisms that enable sensitive and specific biosensors, suitable for measurements in multiple areas; Design of novel biorecognition elements and appropriately designed transducing systems to enable adaptable and/or reconfigurable operating parameters in response to environmental changes or application needs at levels of device, system, or data analysis; Development of adaptive and/or evolvable biosensing systems for detection of novel target analytes or analytes under novel conditions; Novel
Historical details
- Status
- Closed
- First captured
- November 22, 2025
- Publisher reference
- 320536
Free. One email, sent if this program reopens or a close match to it opens. We watch for 12 months, then stop. No list.
Related opportunities
- Biomedical Technology Optimization and Dissemination Center (BTOD) (RM1 - Clinical Trial Not Allowed)National Institutes of HealthCloses Jan 2029
- Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)National Institutes of HealthCloses Mar 2027
- Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)National Institutes of HealthCloses Mar 2027
- Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)National Institutes of HealthCloses Mar 2029Up to $250K
- NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)National Institutes of HealthCloses Jul 2029Up to $500K